Increased by +7.02%
Dollar Volume
144.19 K
Market Cap.
397.86 M
Shares Float
8.59 M
Shares Outstanding
20.88 M
Price / Earnings
20D Range
11.51 19.73
50D Range
10.90 19.73
200D Range
10.90 20.70
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.